Stay updated with breaking news from Broad Second Generation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studiesPhase
18.08.2022 - Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update 18.08.2022 / 13:05 The issuer is solely responsible for the content of this ...
Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenzaCureVac eligible to a €10 million milestone
Investegate announcements from CureVac, CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
25.05.2022 - Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update 25.05.2022 / 13:05 The issuer is solely responsible for the content of this announcement. CureVac ...